Scholars Central

Conference abstractPublished 14 Jun 2018

In vitro and in vivo activity of opioid cyclopeptide with mu/delta agonist profile

Authors: Katarzyna Gach-Janczak, Justyna Piekielna-Ciesielska, Anna Adamska-Bartlomiejczyk, Karol Wtorek, Federica Ferrari, Girolamo Calo, Agata Szymaszkiewicz, Anna Janecka

Medical University of Lodz, Poland University of Ferrara, Italy

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Centrally acting opioid agonists, such as morphine, are the most widely used analgesics for the treatment of severe pain. Among the three types of classic opioid receptors, mu, delta and kappa, the mu receptor was identified as primarily responsible for the pain-relieving effects but also responsible for a number of undesired side effects, including sedation, respiratory depression, inhibition of gastrointestinal transit, tolerance and physical dependence. In the previous decades, chemists and pharmacologists focused on obtaining analogs with high selectivity for one opioid receptor type. More recently, the development of compounds with mixed opioid profile is gaining a lot of interest eg. synergistic antinociceptive effects in response to the mu and delta receptor activation were observed in several in vivo studies. In this study we have shown that the replacement of the tyrosine residue in the mu-selective opioid ligand Tyr-c[D-Lys-Phe-Asp]NH2 with 2',6'-dimethyltyrosine (Dmt) produced a cyclopeptide Dmt-c[D-Lys-Phe-Asp]NH2 with mu-delta opioid receptor profile. This new analog showed improved antinociception in the hot-plate test as compared to the parent peptide but also significantly inhibited the gastrointestinal transit. Using the bioluminescence resonance energy transfer (BRET) assay it was shown that this analog was biased toward Ã?²-arrestin. To the best of our knowledge, it is the first reported Ã?²-arrestin biased opioid analog of a peptide structure. Our data are in accordance with earlier reports indicating that various in vivo activities of opioid agonists arise not only from the activation of one or more opioid receptors, but also from promoting G-protein or Ã?²-arrestin pathways.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedicinal Chemistry
  • SubjectChemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Katarzyna Gach-Janczak”
  • BylineArticles whose byline prints “Justyna Piekielna-Ciesielska”
  • BylineArticles whose byline prints “Anna Adamska-Bartlomiejczyk”
  • BylineArticles whose byline prints “Karol Wtorek”
  • BylineArticles whose byline prints “Federica Ferrari”
  • BylineArticles whose byline prints “Girolamo Calo”
  • BylineArticles whose byline prints “Agata Szymaszkiewicz”
  • BylineArticles whose byline prints “Anna Janecka”